TOT BIOPHARM International Valuation

Is 1875 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1875 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1875's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1875's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1875?

Key metric: As 1875 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1875. This is calculated by dividing 1875's market cap by their current revenue.
What is 1875's PS Ratio?
PS Ratio	1.4x
Sales	CN¥973.17m
Market Cap	CN¥1.35b

1875 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	17.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 1875's PS Ratio compare to its peers?

The above table shows the PS ratio for 1875 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	16x
2142 HBM Holdings	1.6x	n/a	HK$879.3m
2181 Mabpharm	8x	n/a	HK$1.3b
2126 JW (Cayman) Therapeutics	2.9x	44.8%	HK$562.4m
6998 Genor Biopharma Holdings	51.5x	n/a	HK$831.6m
1875 TOT BIOPHARM International	1.4x	20.5%	HK$1.5b

Price-To-Sales vs Peers: 1875 is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (16x).

Price to Sales Ratio vs Industry

How does 1875's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	11.0x	29.4%
1875 TOT BIOPHARM International	1.4x	20.5%	US$186.90m
1530 3SBio	1.6x	9.5%	US$1.92b
6826 Shanghai Haohai Biological Technology	2.2x	11.8%	US$1.79b

14 Companies		Estimated Growth	Market Cap
Industry Avg.	11.0x	43.1%
1875 TOT BIOPHARM International	1.4x	n/a	US$186.90m

No more companies

Price-To-Sales vs Industry: 1875 is good value based on its Price-To-Sales Ratio (1.4x) compared to the Hong Kong Biotechs industry average (11x).

Price to Sales Ratio vs Fair Ratio

What is 1875's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1875 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.4x
Fair PS Ratio	2.7x

Price-To-Sales vs Fair Ratio: 1875 is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.